11 Other financial assets
|
|
Loans associates and joint ventures |
|
Other participating interests |
|
Other receivables |
|
Other |
|
Total |
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Balance at 1 January 2020 |
|
3 |
|
150 |
|
103 |
|
7 |
|
263 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
- |
|
(2) |
|
(2) |
- Acquisitions |
|
- |
|
- |
|
- |
|
4 |
|
4 |
- Disposals |
|
- |
|
(47) |
|
- |
|
- |
|
(47) |
- Capital payments |
|
- |
|
11 |
|
- |
|
- |
|
11 |
- Loans granted/ |
|
1 |
|
- |
|
8 |
|
- |
|
9 |
- Repayments |
|
- |
|
- |
|
(5) |
|
4 |
|
(1) |
- Exchange differences |
|
- |
|
- |
|
(10) |
|
- |
|
(10) |
- Transfers |
|
- |
|
- |
|
(7) |
|
(4) |
|
(11) |
- Changes in fair value |
|
- |
|
106 |
|
- |
|
- |
|
106 |
- Other |
|
- |
|
(1) |
|
(6) |
|
- |
|
(7) |
Balance at 31 December 2020 |
|
4 |
|
219 |
|
83 |
|
9 |
|
315 |
|
|
|
|
|
|
|
|
|
|
|
Changes: |
|
|
|
|
|
|
|
|
|
|
- Charged to the income statement |
|
- |
|
- |
|
(14) |
|
(2) |
|
(16) |
- Disposals |
|
- |
|
(123) |
|
- |
|
- |
|
(123) |
- Capital payments |
|
- |
|
35 |
|
- |
|
- |
|
35 |
- Loans granted/ |
|
- |
|
- |
|
10 |
|
- |
|
10 |
- Repayments/ |
|
- |
|
- |
|
(31) |
|
1 |
|
(30) |
- Exchange differences |
|
- |
|
- |
|
3 |
|
- |
|
3 |
- Transfers |
|
(3) |
|
14 |
|
(20) |
|
(4) |
|
(13) |
- Changes in fair value |
|
- |
|
46 |
|
- |
|
- |
|
46 |
Balance at 31 December 2021 |
|
1 |
|
191 |
|
31 |
|
4 |
|
227 |
‘Disposals’ includes the divestment of part of DSM’s minority share in Amyris, Inc. (€105 million) and other participating interests held by DSM Venturing (€18 million).
‘Changes in fair value’ consists mainly of the value increase of our minority share in Amyris, Inc. (€68 million) and the fair value adjustment of DSM’s share in BCPE Max Dutch JVCo B.V. (€36 million). These changes are posted to the Fair value reserve in Other comprehensive income.